Novo Nordisk AS (WBO:NNO2) Cash Payments for Loans


WBO:NNO2 Novo Nordisk AS WBO:NNO2
71 GF Score
Price €43.21
GF Value €121.19
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is Novo Nordisk AS Cash Payments for Loans?

Cash Payments for Loans only applicable to companies reporting Cash Flow from Operations in direct method.

WBO:NNO2
71GF Score
Novo Nordisk AS WBO:NNO2
Cash Payments for Loans is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Novo Nordisk AS (WBO:NNO2) Overvalued in 2026?

Based on GuruFocus' analysis, Novo Nordisk AS stock appears to be undervalued. The current stock price of €43.21 is trading 64.3% below its estimated GF Value™ of €121.19. GuruFocus considers Novo Nordisk AS to be Significantly Undervalued.

Key valuation signals for WBO:NNO2:

  • Cash Payments for Loans:
  • GF Value™: €121.19 vs. price of €43.21 (64.3% below fair value)
  • GF Score™: 71/100 with 4 warning signs

No single metric tells the full story. See the WBO:NNO2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Novo Nordisk AS Business Description

Address Novo Alle 1, Bagsvaerd, DNK, 2880
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
71GF Score

Get the complete analysis for WBO:NNO2

Cash Payments for Loans is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€43.21
Price
€121.19
GF Value